Find out how to get $100 off your first GLP-1 treatment from Regenics Here's how you can get started with Regenics today and see if you're a fit for GLP-1 weight loss treatments
Real-world outcomes: According to a 72-week phase 3b trial, adults with obesity (but without diabetes) treated with tirzepatide were significantly more likely to lose at least 10% or 15% of their body weight than those treated with semaglutide
This hepatic effect operates through glucagon receptor activation and has implications for anyone studying metabolic syndrome comprehensively
GLP-1 stimulation in the microbiome Human intestinal cells show Akkermansias effect on GLP-1 production Akkermansia secretes p9 protein which stimulates GLP-1 production Clostridium butyricum increases GLP-1* Dose-dependent increase of GLP-1 by Clostridium butyricum in a cell-based assay *Based on internal Pendulum R&D data Breakthrough clinical research Were continually pushing the boundaries in scientific research, and were excited to conduct a human clinical trial on GLP-1 and the gut microbiome
Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial
In agreement with experimental studies, GLP-1 analogues, particularly liraglutide, sustain the maintenance of -cell function in obese individuals with early T2D, and these effects are presumably independent of weight loss (42, 43)
